Disodium etidronate in Paget's disease
Disodium etidronate was the first bisphosphonate to be used clinically in the management of Paget's disease.
Adverse effects include:
- nausea
- diarrhoea
- in 5% of patients there may be an increase in bone pain during the first four weeks or so of treatment
- at higher doses there is an increased incidence of spontaneous fractures because of demineralization that occurs with high doses
There have now been developed second- and third- generation bisphosphonates.
The summary of product characteristics should be consulted before prescribing this drug.
Related pages
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page